secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2022-07-19T23:59:59+00:00
Accession:  0001193125-22-196671
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INOVIO cuts 18% workforce (55 employees) and 86% of contractors to extend cash runway to Q3 2024
--------------------------------------------------------------------------------

- Headcount reduced by 55 employees (18% of full-time staff) and 86% of contractor agreements terminated.
- Expected to reduce operating expenses by ~30% over 18 months; cash runway extended into Q3 2024.
- One-time pre-tax charge of $1.6 million in Q3 2022; cash payments substantially completed by Sept 30, 2022.
- Focus shifts to heterologous boost strategy for COVID-19 vaccine (INO-4800) and HPV programs; key data readouts later in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522196671/0001193125-22-196671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522196671/d382508d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-196671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer